How well does Camzyos(mavacamten) work?

CAMZYOS significantly improves functional capacity and symptoms in adults with obstructive HCM.

Clinical Efficacy and Therapeutic Outcomes of CAMZYOS

CAMZYOS has demonstrated efficacy in improving exercise capacity, reducing LVOT gradients, and alleviating symptoms in adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy. Clinical trials showed a higher proportion of patients achieving meaningful improvements in peak oxygen consumption and NYHA class compared to placebo. Secondary benefits include reductions in NT-proBNP and cardiac troponin I, as well as improvements in health status and quality of life measures. The therapeutic effect in non-obstructive HCM or other populations is not specified in the description.